Pluripotent stem cell-based cancer therapy: Promise and challenges

Science Translational Medicine

Volumn 4, Issue 127, 2012, Pages

  Sharkis, Saul J ^a   Jones, Richard J ^a   Civin, Curt ^b   Jang, Yoon Young ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CLINICAL EFFECTIVENESS; EMBRYONIC STEM CELL; ENGRAFTMENT; EVIDENCE BASED MEDICINE; GENE EXPRESSION REGULATION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; NUCLEAR REPROGRAMMING; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SOMATIC CELL THERAPY; STEM CELL TRANSPLANTATION; T LYMPHOCYTE RECEPTOR GENE; TRANSLATIONAL RESEARCH; ANIMAL; BLOOD DISEASE; CYTOLOGY; NEOPLASM;

ADULT STEM CELLS; ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84859116568     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003920     Document Type: Review

References (37)

1. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, S. Yamanaka, Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
2. S. M. Wu, K. Hochedlinger, Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat. Cell Biol. 13, 497-505 (2011).
3. Y. S. Chun, P. Chaudhari, Y. Y. Jang, Applications of patient- specific induced pluripotent stem cells; Focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int. J. Biol. Sci. 6, 796-805 (2010).
4. R. Maehr, S. Chen, M. Snitow, T. Ludwig, L. Yagasaki, R. Goland, R. L. Leibel, D. A. Melton, Generation of pluripotent stem cells from patients with type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A. 106, 15768-15773 (2009).
5. J. Hanna, M. Wernig, S. Markoulaki, C. W. Sun, A. Meissner, J. P. Cassady, C. Beard, T. Brambrink, L. C. Wu, T. M. Townes, R. Jaenisch, Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920-1923 (2007).
6. S. Kriks, J. W. Shim, J. Piao, Y. M. Ganat, D. R. Wakeman, Z. Xie, L. Carrillo-Reid, G. Auyeung, C. Antonacci, A. Buch, L. Yang, M. F. Beal, D. J. Surmeier, J. H. Kordower, V. Tabar, L. Studer, Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551 (2011).
7. H. Liu, Y. Kim, S. Sharkis, L. Marchionni, Y. Y. Jang, In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci. Transl. Med. 3, 82ra39 (2011).
8. S. M. Choi, Y. Kim, H. Liu, P. Chaudhari, Z. Ye, Y. Y. Jang, Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells. Cell Cycle 10, 2423-2427 (2011).
9. L. Yang, D. Baltimore, Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 102, 4518-4523 (2005).
10. M. E. Brown, E. Rondon, D. Rajesh, A. Mack, R. Lewis, X. Feng, L. J. Zitur, R. D. Learish, E. F. Nuwaysir, Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS ONE 5, e11373 (2010).
11. Y. H. Loh, O. Hartung, H. Li, C. Guo, J. M. Sahalie, P. D. Manos, A. Urbach, G. C. Heff ner, M. Grskovic, F. Vigneault, M. W. Lensch, I. H. Park, S. Agarwal, G. M. Church, J. J. Collins,S. Irion, G. Q. Daley, Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7, 15-19 (2010).
12. T. Seki, S. Yuasa, M. Oda, T. Egashira, K. Yae, D. Kusumoto, H. Nakata, S. Tohyama, H. Hashimoto, M. Kodaira, Y. Okada, H. Seimiya, N. Fusaki, M. Hasegawa, K. Fukuda, Generation of induced pluripotent stem cells from human terminally diff erentiated circulating T cells. Cell Stem Cell 7, 11-14 (2010).
13. J. Staerk, M. M. Dawlaty, Q. Gao, D. Maetzel, J. Hanna, C. A. Sommer, G. Mostoslavsky, R. Jaenisch, Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7, 20-24 (2010).
14. T. Serwold, K. Hochedlinger, J. Swindle, J. Hedgpeth, R. Jaenisch, I. L. Weissman, T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell. Proc. Natl. Acad. Sci. U.S.A. 107, 18939-18943 (2010).
15. R. A. Wilke, D. W. Lin, D. M. Roden, P. B. Watkins, D. Flockhart, I. Zineh, K. M. Giacomini, R. M. Krauss, Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916 (2007).
16. D. Kim, C. H. Kim, J. I. Moon, Y. G. Chung, M. Y. Chang, B. S. Han, S. Ko, E. Yang, K. Y. Cha, R. Lanza, K. S. Kim, Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4, 472-476 (2009).
17. J. Yu, K. Hu, K. Smuga-Otto, S. Tian, R. Stewart, I. I. Slukvin, J. A. Thomson, Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801 (2009).
18. L. Warren, P. D. Manos, T. Ahfeldt, Y. H. Loh, H. Li, F. Lau, W. Ebina, P. K. Mandal, Z. D. Smith, A. Meissner, G. Q. Daley, A. S. Brack, J. J. Collins, C. Cowan, T. M. Schlaeger, D. J. Rossi, Highly efficient reprogramming to pluripotency and directed diff erentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630 (2010).
19. S. M. Choi, H. Liu, P. Chaudhari, Y. Kim, L. Cheng, J. Feng, S. Sharkis, Z. Ye, Y. Y. Jang, Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood 118, 1801-1805 (2011).
20. B. K. Chou, P. Mali, X. Huang, Z. Ye, S. N. Dowey, L. M. Resar, C. Zou, Y. A. Zhang, J. Tong, L. Cheng, Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 21, 518-529 (2011).
21. K. Hu, J. Yu, K. Suknuntha, S. Tian, K. Montgomery, K. D. Choi, R. Stewart, J. A. Thomson, I. I. Slukvin, Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 117, e109-e119 (2011).
22. A. Gore, Z. Li, H. L. Fung, J. E. Young, S. Agarwal, J. Antosiewicz- Bourget, I. Canto, A. Giorgetti, M. A. Israel, E. Kiskinis, J. H. Lee, Y. H. Loh, P. D. Manos, N. Montserrat, A. D. Panopoulos, S. Ruiz, M. L. Wilbert, J. Yu, E. F. Kirkness, J. C. Izpisua Belmonte, D. J. Rossi, J. A. Thomson, K. Eggan, G. Q. Daley, L. S. Goldstein, K. Zhang, Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63-67 (2011).
23. D. S. Kaufman, Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114, 3513-3523 (2009).
24. Z. Ye, L. Cheng, Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. Regen. Med. 5, 521-530 (2010).
25. Z. Song, J. Cai, Y. Liu, D. Zhao, J. Yong, S. Duo, X. Song, Y. Guo, Y. Zhao, H. Qin, X. Yin, C. Wu, J. Che, S. Lu, M. Ding, H. Deng, Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res. 19, 1233-1242 (2009).
26. H. Liu, Z. Ye, Y. Kim, S. Sharkis, Y. Y. Jang, Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 51, 1810-1819 (2010).
27. S. T. Rashid, S. Corbineau, N. Hannan, S. J. Marciniak, E. Miranda, G. Alexander, I. Huang-Doran, J. Griffin, L. Ahrlund-Richter, J. Skepper, R. Semple, A. Weber, D. A. Lomas, L. Vallier, Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120, 3127-3136 (2010).
28. G. J. Sullivan, D. C. Hay, I. H. Park, J. Fletcher, Z. Hannoun, C. M. Payne, D. Dalgetty, J. R. Black, J. A. Ross, K. Samuel, G. Wang, G. Q. Daley, J. H. Lee, G. M. Church, S. J. Forbes, J. P. Iredale, I. Wilmut, Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 51, 329-335 (2010).
29. K. Kim, A. Doi, B. Wen, K. Ng, R. Zhao, P. Cahan, J. Kim, M. J. Aryee, H. Ji, L. I. Ehrlich, A. Yabuuchi, A. Takeuchi, K. C. Cunniff , H. Hongguang, S. McKinney-Freeman, O. Naveiras, T. J. Yoon, R. A. Irizarry, N. Jung, J. Seita, J. Hanna, P. Murakami, R. Jaenisch, R. Weissleder, S. H. Orkin, I. L. Weissman, A. P. Feinberg, G. Q. Daley, Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-290 (2010).
30. J. M. Polo, S. Liu, M. E. Figueroa, W. Kulalert, S. Eminli, K. Y. Tan, E. Apostolou, M. Stadtfeld, Y. Li, T. Shioda, S. Natesan, A. J. Wagers, A. Melnick, T. Evans, K. Hochedlinger, Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28, 848-855 (2010).
31. O. Bar-Nur, H. A. Russ, S. Efrat, N. Benvenisty, Epigenetic memory and preferential lineage-specific diff erentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17-23 (2011).
32. R. Szydlo, J. M. Goldman, J. P. Klein, R. P. Gale, R. C. Ash, F. H. Bach, B. A. Bradley, J. T. Casper, N. Flomenberg, J. L. Gajewski, E. Gluckman, P. J. Henslee-Downey, J. M. Hows, N. Jacobsen, H. J. Kolb, B. Lowenberg, T. Masaoka, P. A. Rowlings, P. M. Sondel, D. W. van Bekkum, J. J. van Rood, M. R. Vowels, M. J. Zhang, M. M. Horowitz, Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J. Clin. Oncol. 15, 1767-1777 (1997).
33. P. J. Shaw, F. Kan, K. Woo Ahn, S. R. Spellman, M. Aljurf, M. Ayas, M. Burke, M. S. Cairo, A. R. Chen, S. M. Davies, H. Frangoul, J. Gajewski, R. P. Gale, K. Godder, G. A. Hale, M. B. Heemskerk, J. Horan, N. Kamani, K. A. Kasow, K. W. Chan, S. J. Lee, W. H. Leung, V. A. Lewis, D. Miklos, M. Oudshoorn, E. W. Petersdorf, O. Ringdén, J. Sanders, K. R. Schultz, A. Seber, M. Setterholm, D. A. Wall, L. Yu, M. A. Pulsipher, Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 116, 4007-4015 (2010).
34. A. Dew, D. Collins, A. Artz, E. Rich, W. Stock, K. Swanson, K. van Besien, Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: The need for new donor options. Biol. Blood Marrow Transplant. 14, 938-941 (2008).
35. L. Luznik, P. V. O'Donnell, H. J. Symons, A. R. Chen, M. S. Leff ell, M. Zahurak, T. A. Gooley, S. Piantadosi, M. Kaup, R. F. Ambinder, C. A. Huff , W. Matsui, J. Bolaños-Meade, I. Borrello, J. D. Powell, E. Harrington, S. Warnock, M. Flowers, R. A. Brodsky, B. M. Sandmaier, R. F. Storb, R. J. Jones, E. J. Fuchs, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641-650 (2008).
36. C. G. Brunstein, E. J. Fuchs, S. L. Carter, C. Karanes, L. J. Costa, J. Wu, S. M. Devine, J. R. Wingard, O. S. Aljitawi, C. S. Cutler, M. H. Jagasia, K. K. Ballen, M. Eapen, P. V. O'Donnell; Blood and Marrow Transplant Clinical Trials Network, Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118, 282-288 (2011).
37. T. A. Yap, M. Gerlinger, P.A. Futreal, L. Pusztai, C. Swanton, Intratumor heterogeneity: Seeing the wood for the trees. Sci Transl. Med. 4, 127ps10 (2012).